Axogen reported third-quarter revenue of $75.8 million, a 26.2% increase from the prior year period, and raised its full-year 2026 revenue guidance to at least $290 million, representing growth of at least 29%. The company also completed the acquisition of BioCircuit Technologies for $200 million using proceeds from a recent equity offering. Axogen reported adjusted net income of $13.1 million and adjusted EBITDA of $13.4 million for the quarter. The firm is a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function.
